---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286820837.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 9.79% to $9.95 on Monday, marking the third consecutive day of losses. The stock is currently 51.61% below its 52-week high of $20.56. In comparison, competitors had mixed results, with Vanda Pharmaceuticals down 3.18%, Fortress Biotech up 2.90%, and Viking Therapeutics down 5.22%. Trading volume was 232,939, below the 50-day average of 263,554."
datetime: "2026-05-18T21:20:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286820837.md)
  - [en](https://longbridge.com/en/news/286820837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286820837.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) shed 9.79% to $9.95 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.32% to 49,686.12 and the NASDAQ Composite Index falling 0.51% to 26,090.73.

This was the stock's third consecutive day of losses.

Corbus Pharmaceuticals Holdings Inc. closed 51.61% short of its 52-week high of $20.56, which the company achieved on October 20th.

The stock underperformed when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc. (VNDA) fell 3.18% to $6.08, Fortress Biotech Inc. (FBIO) rose 2.90% to $2.48, and Viking Therapeutics Inc. (VKTX) fell 5.22% to $28.69.

Trading volume (232,939) remained 30,615 below its 50-day average volume of 263,554.

Data source: Dow Jones Market Data, FactSet. Data compiled May 18, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-18-26 1720ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)